Contrasting Surmodics (SRDX) and Its Peers
Surmodics (NASDAQ: SRDX) is one of 80 publicly-traded companies in the “Medical Equipment, Supplies & Distribution” industry, but how does it weigh in compared to its peers? We will compare Surmodics to related companies based on the strength of its analyst recommendations, profitability, valuation, institutional ownership, earnings, risk and dividends.
This table compares Surmodics and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
84.5% of Surmodics shares are held by institutional investors. Comparatively, 65.6% of shares of all “Medical Equipment, Supplies & Distribution” companies are held by institutional investors. 6.4% of Surmodics shares are held by company insiders. Comparatively, 12.0% of shares of all “Medical Equipment, Supplies & Distribution” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
This is a summary of current recommendations and price targets for Surmodics and its peers, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Surmodics currently has a consensus price target of $40.00, indicating a potential upside of 26.58%. As a group, “Medical Equipment, Supplies & Distribution” companies have a potential upside of 6.40%. Given Surmodics’ stronger consensus rating and higher possible upside, research analysts plainly believe Surmodics is more favorable than its peers.
Valuation and Earnings
This table compares Surmodics and its peers gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Surmodics||$73.11 million||$3.92 million||108.97|
|Surmodics Competitors||$975.11 million||$120.37 million||225.39|
Surmodics’ peers have higher revenue and earnings than Surmodics. Surmodics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Risk & Volatility
Surmodics has a beta of 0.83, indicating that its stock price is 17% less volatile than the S&P 500. Comparatively, Surmodics’ peers have a beta of 0.93, indicating that their average stock price is 7% less volatile than the S&P 500.
Surmodics beats its peers on 7 of the 13 factors compared.
Surmodics Company Profile
Surmodics, Inc. is a provider of medical device and in vitro diagnostic technologies to the healthcare industry. The Company operates through two segments: Medical Device and In Vitro Diagnostics. The Company’s Medical Device segment consists of surface modification coating technologies to improve access, deliverability and predictable deployment of medical devices; international cardiology and peripheral balloon design, development and manufacturing, as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device. The Company’s In Vitro Diagnostics segment manufactures or sells components for in vitro diagnostic immunoassay and molecular tests. The In Vitro Diagnostics segment manufactures and sells surface coatings to the diagnostic, biomedical research and life science markets. In Vitro Diagnostics segment offers protein stabilization reagents, substrates, antigens and surface coatings.
Receive News & Ratings for Surmodics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surmodics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.